For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Vyndamax and Tafamidis meglumine represents a true change. These groundbreaking therapies stabilize the transthyretin protein, slowing its harmful build-up and alleviating the burden of the condition . Patients are now seeing positive o